These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 21760530)

  • 1. CpG oligodeoxynucleotide stimulates protective innate immunity against human renal cell carcinoma xenografted in nude mice.
    Zhou PJ; Ma BB; He W; Xu D; Wang XH
    J Immunother; 2011 Sep; 34(7):535-41. PubMed ID: 21760530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
    Chagnon F; Tanguay S; Ozdal OL; Guan M; Ozen ZZ; Ripeau JS; Chevrette M; Elhilali MM; Thompson-Snipes LA
    Clin Cancer Res; 2005 Feb; 11(3):1302-11. PubMed ID: 15709202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN.
    De Cesare M; Sfondrini L; Campiglio M; Sommariva M; Bianchi F; Perego P; van Rooijen N; Supino R; Rumio C; Zunino F; Pratesi G; Tagliabue E; Balsari A
    J Immunother; 2010 Jan; 33(1):8-15. PubMed ID: 19952960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy.
    De Cesare M; Calcaterra C; Pratesi G; Gatti L; Zunino F; Mènard S; Balsari A
    Clin Cancer Res; 2008 Sep; 14(17):5512-8. PubMed ID: 18765543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antitumor effect of CpG oligonucleotides on human neuroblastoma xenografts in nude mice].
    Yao QH; Tang YJ; Gao FH; Tang JY
    Ai Zheng; 2009 Apr; 28(4):344-9. PubMed ID: 19622291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
    Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
    Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
    Daftarian P; Song GY; Ali S; Faynsod M; Longmate J; Diamond DJ; Ellenhorn JD
    Cancer Res; 2004 Aug; 64(15):5407-14. PubMed ID: 15289349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
    Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
    Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen.
    Auf G; Carpentier AF; Chen L; Le Clanche C; Delattre JY
    Clin Cancer Res; 2001 Nov; 7(11):3540-3. PubMed ID: 11705874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor therapy with bacterial DNA and toxin: complete regression of established tumor induced by liposomal CpG oligodeoxynucleotides plus interleukin-13 cytotoxin.
    Ishii KJ; Kawakami K; Gursel I; Conover J; Joshi BH; Klinman DM; Puri RK
    Clin Cancer Res; 2003 Dec; 9(17):6516-22. PubMed ID: 14695156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
    Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
    Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radio frequency ablation combined with interleukin-2 induces an antitumor immune response to renal cell carcinoma in a murine model.
    Kroeze SG; Daenen LG; Nijkamp MW; Roodhart JM; de Gast GC; Bosch JL; Jans JJ
    J Urol; 2012 Aug; 188(2):607-14. PubMed ID: 22704448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells.
    Kim HA; Ko HM; Ju HW; Kim KJ; Roh SG; Lee HK; Im SY
    Cancer Lett; 2009 Feb; 274(1):160-4. PubMed ID: 18952369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK and NKT cell-independent contribution of interleukin-15 to innate protection against mucosal viral infection.
    Gill N; Rosenthal KL; Ashkar AA
    J Virol; 2005 Apr; 79(7):4470-8. PubMed ID: 15767447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix.
    Inamoto T; Yamochi T; Ohnuma K; Iwata S; Kina S; Inamoto S; Tachibana M; Katsuoka Y; Dang NH; Morimoto C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3470-7. PubMed ID: 16740772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA.
    Ballas ZK; Rasmussen WL; Krieg AM
    J Immunol; 1996 Sep; 157(5):1840-5. PubMed ID: 8757300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
    Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
    J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model.
    Cho HC; Kim BH; Kim K; Park JY; Chang JH; Kim SK
    Int Immunopharmacol; 2008 Oct; 8(10):1401-7. PubMed ID: 18687302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis.
    Xiong Z; Gharagozlou S; Vengco I; Chen W; Ohlfest JR
    Clin Cancer Res; 2008 Sep; 14(17):5484-93. PubMed ID: 18765540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
    Mutwiri G; Benjamin P; Soita H; Babiuk LA
    Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.